The 2026 regulatory changes opened a path toward licensed compounding access in the United States, but the FDA's Pharmacy Compounding Advisory Committee decision in July 2026 will determine whether that path expands or narrows
According to the retatrutide trial results, the share of people who quit due to side effects was similar to that in other GLP-1 trials (between 4% and 11%, depending on the dose)
The Critical Distinction: Mechanism and Magnitude It's essential to understand that probiotic GLP-1 supplements work through fundamentally different mechanisms than pharmaceutical medications
doi: 10.1080/13543784.2025.2473062, 22
Tirzepatide, sold as Mounjaro, is a different molecule from Eli Lilly and is not part of this Semaglutide patent expiry story
The paper provides other measurements like changes in drinking days and changes in heavy drinking days and changes in drinks per drinking day, but its the same story: Either no benefit or no difference